Medigene Ag

Universitaet Zu Koeln

Ludwig-maximilians-universitaet

The University of Texas System

Novartis Ag

Gsf-international Research Institute for Environment and Health

Gsf&mdash;forschungszentrum Fur Umwelt Und Gesundheit Gmbh

Gsf-forschungszentrum Für Umwelt Gesundheit, Gmbh

Michael Hallek

Christoph Bogedain

Alexander Burger

Anne Girod

Martin Ried

Markus Hoerer

Gerhard Maass

Luca Perabo

Mirko Ritter

Gerd Maass

Hildegard Buening

John Nieland

Paul William Manley

Markus Warmuth

Doriano Fabbro

Moshe Talpaz

Nicholas J Donato

Kerstin Lux

Ji Wu

Clemens Wendtner

Jorge Boucas

Michael Schaeffer

Michaela Schneiderbauer

Sascha Weidler

Doris Michl

Ulrich Moebius

Christof Körner

Markus Hörer

Gilbert Deleage

Martin Reid

Kerstin Pinotossi

Daniela Kuehn

Daniela Goldnau

Nadja Huttner

Joerg Enssle

Markus HÖRER

Daniela KÜHN

Hildegard BÜNING

Jörg Enssle

The present invention is related to a structural protein of a parvovirus with an amino acid insertion at the insertion site I-453, a library comprising the protein, a multimeric structure comprising the protein, a nucleic acid encoding the protein, a vector, virus or cell comprising the nucleic acid, a process for the preparation of the protein, a medicament comprising the protein, nucleic acid or multimeric structure as well as methods and uses involving the protein, nucleic acid or multimeric structure.

Mutated structural protein of a parvovirus

The present invention is related to a method for identifying a parvovirus mutated structural protein capable of specifically binding to a binder for an antigen, a parvovirus mutated structural protein which comprises at least one B-cell epitope heterologous to the parvovirus, a multimeric structure comprising the protein, a nucleic acid encoding the protein, a virus or cell comprising the protein, a method of preparing the protein, a medicament comprising the protein, nucleic acid or multimeric structure and its use.

Mutated parvovirus structural proteins as vaccines

The present invention is related to a structural protein of a parvovirus with an amino acid insertion at the insertion site I-453, a library comprising the protein, a multimeric structure comprising the protein, a nucleic acid encoding the protein, a vector, virus, or cell comprising the nucleic acid, a process for the preparation of the protein, a medicament comprising the protein, nucleic acid, or multimeric structure as well as methods and uses involving the protein, nucleic acid, or multimeric structure.

The invention relates to a combination which comprises (a) at least one compound decreasing the c-Src activity and (b) N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine or the monomethanesulfonate salt thereof; to pharmaceutical compositions comprising said combinations; and to a method of treating a warm-blooded animal having leukaemia, especially chronic myelogenous leukaemia, comprising administering to the animal at least one compound inhibiting the activity of a member of the Src kinase family, the Btk kinase family, the Tec kinase family or a Raf kinase inhibitor, in particular inhibiting the c-Src protein tyrosine kinase activity or inhibiting simultaneously the c-Src protein tyrosine kinase activity and the Bcr-Abl tyrosine kinase activity, alone or in combination with a Bcr-Abl inhibitor, in particular N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine.

Use of c-Src inhibitors alone or in combination with STI571 for the treatment of leukaemia

The present invention relates to a structural protein of adeno-associated virus (AAV) which comprises at least one modification which brings about a reduction in the antigenicity, its production and use.

Structural protein of adeno-associated virus with modified antigenicity, its production and its use

Vaccine formulations comprising, viral capsomeres are disclosed along with methods for their production. Therapeutic and prophylactic methods of use for the vaccine formulations are also disclosed.

Papilloma virus truncated L1 protein and fusion protein constructs

The invention relates to a structural protein of adeno-associated virus (AAV) which comprises at least one mutation which brings about an increase in the infectivity of the virus.

AAv scleroprotein, production and use thereof

The invention relates to a scleroprotein of an adeno-associated virus which contains at least one mutation. Said mutation causes the chromatographic properties to be modified. The invention also relates to the production of said scleroprotein and the use thereof.

Scleroprotein of an adeno-associated virus with modified chromatographic properties, the production thereof and use of the same

The invention relates to a structural protein of adeno-associated virus (AAV) that contains at least one modification that reduces the antigenicity of the virus. The invention further relates to the production of the structural protein and to its use.

Vaccine formulations comprising viral capsomeres are disclosed along with methods for their production. Therapeutic and prophylactic methods of use for the vaccine formulations are also disclosed.

Papillomavirus truncated L1 protein and fusion protein constructs

Multiple myeloma is treated by deletion mutants of the gp130 protein of the IL-3 receptor. These mutants inhibit the binding of Hck tyrosine kinase and the growth of tumor cells, particularly myeloma cells.

Inhibition of the proliferation of cells of the multiple myeloma

The present invention provides an Adeno-Associated Virus (AAV) vector having a foreign DNA coding for a protein that boosts immunogenicity of cells. The invention also provides a vaccine containing such a vector and the use of both.

Adeno-associated virus vector for boosting immunogenicity of cells

The invention relates to a medicament for preventing or treating human papilloma virus (HPV)-specific tumors containing at least one fusion protein and optional suitable additives and/or auxiliary agents. Said fusion protein is comprised of at least one L1-protein of one or more papilloma viruses, and is also comprised of at least one E-protein of one or more papilloma viruses, whereby the fusion protein does not contain any papilloma virus non-specific epitopes.

Medicament for the avoidance or treatment of papillomavirus-specific tumour

Growing community of inventors

Schondorf, Germany

Michael Hallek